Pharma Major Lupin

The governmental commission on monitoring foreign investment has approved the buyout of the Russian Biocom (CIA International) by an Indian pharmaceutical company, head of the Federal Anti-Monopoly Service Igor Artemyev said after the commission’s meeting. Lupin will invest USD 200m into Biocom.

“India’s Lupin will buy out 100% shares in Biocom for USD Biocom is the manufacturer of 17 items on the life-saving drugs list,” he added. “The investment which the Indian company expects to inject in line with the business plan in the near term amount to USD 200m,” Artemyev added.

10 December 2015
200.0 mln

Investor profile

Pharma Major Lupin


Company's website:

T: +91 22 6640 2222

Public company

Contact: Dr. Desh Bandhu Gupta, Chairman of the Board of Directors and founder

Lupin Pharmaceuticals Inc. Is the fourth largest pharmaceutical company in India in terms of sales. Lupin specializes in the production of generic and branded drugs as well as pharmaceutic substances. Set up in 1968, the company is now present in over 100 countries worldwide, with its revenue in the 2013-2014 fiscal year coming up to USD 1.8bn, and net profit reaching USD 299.9m. Lupin currently ranks No. 5 generic drugs producer in the USA, and No. 3 pharmaceuticals producer in terms of revenue in India.